Nuo Therapeutics, Inc. (AURX)

SG&A Expense Growth

34.50%

Fiscal year · Period ending:

AURX logo

AURX SG&A Expense Growth

Latest reported34.50%
AURX FY SG&A Growth (YoY) (0.00% → 34.50%)
High-resolution chart · PNG

AURX sg&a expense growth history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Nuo Therapeutics, Inc. SG&A Expense Growth — Annual fiscal periods
Period endingSG&A Expense Growth
34.4995%
-3.5758%
6.945%
3,664.8947%
-76.017%
-53.8714%
-61.6323%
-52.9145%
-36.3314%
-53.3004%
-2.5755%
-10.0692%
7.7792%
103.5928%
8.9362%
50.8561%
-15.1979%
-11.6528%
26.5698%
-36.9639%
-6.2965%
93.3127%
122.9189%
14.1493%
-2.2272%
631.8327%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.